Wilex AG is taking the unusual step of canceling a planned interim analysis of data from a pivotal Phase III trial of its clear cell renal cell carcinoma (ccRCC) drug Rencarex (girentuximab) and seeking permission from European and U.S. drug regulators to complete a final data analysis based on an amended protocol.